XTLBFDA Updates
XTL Announces Receipt of Staff Delist Determination from Nasdaq
XTL Biopharmaceuticals Ltd. has received a delisting notice from Nasdaq due to its failure to file the Annual Report for 2025. The company is already under review for not meeting minimum equity and bid price requirements. XTL intends to request an extension for the suspension of its securities by May 26, 2026, but faces uncertainty regarding the Panel's decision.
Read more →XTLBGeneral
NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MONDAY, JUNE 22, 2026 To the shareholders of XTL Biopharmaceuticals Ltd.: Notice is hereby given that an Extraordinary General Meeting (the " Meeting
XTL Biopharmaceuticals Ltd. has scheduled an Extraordinary General Meeting for June 22, 2026, to discuss key agenda items including the acquisition of a controlling interest in Psyga Bio Ltd. and a private placement of up to $1.5 million. Shareholders will also vote on increasing the company's authorized share capital significantly and appointing new auditors. The company invites shareholders to attend in person or via proxy voting to partake in these crucial decisions.
Read more →XTLBGeneral
▲ +54.8%on this news· ran to +70% by day 1
SHARE PURCHASE AGREEMENT THIS SHARE PURCHASE AGREEMENT (this " Agreement ") made effective as of [ ], 2026 (the " Effective Date "), by and among the current shareholders of the Company listed in Exhibit A attached heret
XTL Biopharmaceuticals Ltd. has entered into a share purchase agreement to acquire 100% of the shares of Psyga Bio Ltd. This agreement, effective from a future date in 2026, stipulates that the current shareholders of Psyga will sell a total of 338,990 Ordinary Shares to XTL. The acquisition is expected to result in Psyga becoming a wholly-owned subsidiary of XTL, pending approvals from the relevant boards and committees as mandated by Israeli law.
Read more →XTLBGeneral
▲ +54.8%on this news· ran to +70% by day 1
XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies
XTL Biopharmaceuticals has announced the acquisition of Psyga Bio, a company specializing in psychedelic therapeutics. This move aims to establish XTL as a key player in the expanding psychedelic market, supported by Psyga's clinical pipeline of seven approved Phase 2a trials and a licensed GMP-ready manufacturing facility. The transaction involves a share exchange that will significantly alter XTL's shareholder structure, and is influenced by recent regulatory advancements in the U.S. regarding psychedelic therapies. The deal also includes provisions for milestone-based equity incentives pending clinical trial achievements.
Read more →XTLBGeneral
XTL Biopharmaceuticals Announces ADS Ratio Change
XTL Biopharmaceuticals Ltd. announced a change in its American Depositary Shares (ADS) ratio, effective March 25, 2026. The new ratio will be one ADS for every 400 ordinary shares, resulting in a reverse split. This change aims to increase the trading price of ADSs, although no guarantees are provided. No fees will be incurred by ADS holders during this process.
Read more →XTLBFDA Updates
XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing
XTL Biopharmaceuticals Ltd. has received a delisting determination from Nasdaq due to its classification as a 'public shell.' The company plans to appeal this decision through a hearing, which will temporarily halt the delisting process. The Nasdaq Staff cited the company's lack of an operating business and failure to meet financial requirements as reasons for the delisting.
Read more →XTLBGeneral
XTL Update on Recent Developments
XTL Biopharmaceuticals Ltd. is working to finalize the acquisition of 85% of NeuroNOS Ltd. from Beyond Air Inc. after signing a Binding Letter of Intent. A shareholders meeting is set for February 17, 2026, to discuss a private placement aimed at addressing compliance with Nasdaq's equity requirements. However, there are uncertainties regarding the acquisition's completion and shareholder approval.
Read more →XTLBFDA Updates
▼ -10.1%on this news· ran to -21% by day 3
XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency
XTL Biopharmaceuticals Ltd. has received a notification from Nasdaq indicating that it does not meet the minimum stockholders' equity requirement for continued listing. The company reported a deficit of $47,000 in its equity. XTL has 45 days to submit a plan to regain compliance, and it is currently evaluating options to address this issue.
Read more →XTLBGeneral
▲ +56.7%on this news
XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
XTL Biopharmaceuticals has announced the acquisition of 85% of NeuroNOS, a company focusing on disease-modifying therapies for Autism Spectrum Disorder. This strategic move aims to address the critical unmet medical need for autism treatments, as no FDA-approved options currently exist. The acquisition includes a team of Nobel Laureates and secured FDA Orphan Drug designations for related conditions, signaling a strong commitment to advancing autism therapeutics.
Read more →XTLBGeneral
▲ +56.7%on this newsshared move
NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON FEBRUARY 17, 2026 To the shareholders of XTL Biopharmaceuticals Ltd.: Notice is hereby given that an Extraordinary General Meeting (the "Meeting") of
XTL Biopharmaceuticals Ltd. has announced an Extraordinary General Meeting (EGM) set for February 17, 2026, in Tel Aviv, Israel. The agenda includes proposals to increase the authorized share capital by 1.45 billion shares and to re-elect Ms. Iris Shapira Yalon as an external director. The company also seeks approval for a private placement of securities amounting to up to $2 million, contingent upon a transaction involving NeuroNOS Ltd.
Read more →XTLBGeneral
▲ +56.7%on this newsshared move
XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
XTL Biopharmaceuticals has agreed to acquire 85% of NeuroNOS, a subsidiary focused on developing therapies for Autism Spectrum Disorder (ASD). This acquisition includes notable scientific leadership, featuring two Nobel Laureates and an established founder in autism research. The deal aims to address significant unmet medical needs, as no FDA-approved disease-modifying treatments currently exist for autism. XTL is positioned to become a key player in this market, with financial commitments aimed at advancing NeuroNOS's innovative programs.
Read more →XTLBGeneral
XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
XTL Biopharmaceuticals Ltd. received a notification from Nasdaq indicating it does not meet the minimum bid price requirement of $1 per share. The company has 180 days to comply, during which its shares will continue to trade. XTL may seek an extension for compliance if necessary, but there are no guarantees of success in regaining compliance with Nasdaq listing standards.
Read more →XTLBGeneral
NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 21, 2025 To the shareholders of XTL Biopharmaceuticals Ltd.: Notice is hereby given that an Annual and Extraordinary General Meeting (
XTL Biopharmaceuticals Ltd. has announced an Annual and Extraordinary General Meeting for shareholders on July 21, 2025, at their legal offices in Bnei Brak, Israel. The agenda includes discussions on financial statements, re-appointment of auditors, and potential grants of stock options. Shareholders must be registered by June 18, 2025, to vote at the meeting. The Board of Directors recommends voting in favor of the items on the agenda.
Read more →XTLBGeneral
▼ -11.4%on this news
XTL Names Mr. Noam Band as its New Chief Executive Officer
XTL Biopharmaceuticals Ltd. has appointed Noam Band as its new Chief Executive Officer. Band brings significant experience from his previous roles in technology and digital marketing. His leadership is expected to drive the company towards new opportunities and enhance operational excellence. The Board expresses confidence in his ability to contribute to the company's growth.
Read more →XTLBGeneral
XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million
XTL Biopharmaceuticals Ltd. has completed the acquisition of The Social Proxy, an AI web data company, enhancing its IP portfolio. The transaction involved a private placement of $1.5 million, allowing XTL to support Social Proxy's growth. Social Proxy will operate as a wholly owned subsidiary, with its shareholders joining XTL's board of directors.
Read more →XTLBGeneral
▲ +5.4%on this news· ran to +20% by day 3
NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 22, 2024 To the shareholders of XTL Biopharmaceuticals Ltd.: Notice is hereby given that an Annual and Extraordinary General Meeting (
XTL Biopharmaceuticals Ltd. will hold its Annual and Extraordinary General Meeting on July 22, 2024, at the offices of its attorneys in Bnei Brak, Israel. Key agenda items include reviewing the auditor's report, reappointing auditors, and re-electing board members. Additionally, shareholders are expected to approve the terms of acquisition for The Social Proxy Ltd., which involves significant cash and equity considerations. Those eligible to vote must hold shares as of June 24, 2024.
Read more →XTLBGeneral
XTL Entered Definitive Agreement to Acquire The Social Proxy
XTL Biopharmaceuticals Ltd. has entered into a definitive agreement to acquire The Social Proxy, an AI web data company. The acquisition involves a private placement that will give The Social Proxy's shareholders a significant stake in XTL. This move is part of XTL's strategy to enhance its asset portfolio in high-growth markets. The transaction is contingent on customary approvals and conditions.
Read more →XTLBGeneral
SHARE PURCHASE AGREEMENT THIS SHARE PURCHASE AGREEMENT (this " Agreement ") made effective as of
XTL Biopharmaceuticals Ltd. has entered into a share purchase agreement to acquire 100% of the shares of The Social Proxy Ltd., making it a wholly-owned subsidiary. The acquisition involves the purchase of a total of 10,813 ordinary shares against cash and equity considerations. Both companies’ boards of directors have approved the agreement, noting that the transaction is in their best interests. This deal is expected to strengthen XTL's market position and operational capabilities.
Read more →XTLBConferences/Events
NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON APRIL 30, 2024 To the shareholders of XTL Biopharmaceuticals Ltd.: Notice is hereby given that an Extraordinary General Meeting (the "Meeting") of the
XTL Biopharmaceuticals Ltd. has announced an Extraordinary General Meeting of shareholders set to take place on April 30, 2024, at 4:00 p.m. Israel time. The meeting will be held at the offices of the company's attorneys in Bnei Brak, Israel, where shareholders can vote on proposed agenda items. Shareholders eligible to vote are those on record as of March 28, 2024, and there are provisions for proxy voting for those who cannot attend in person. The company encourages shareholders to participate either in person or by proxy to ensure their votes are counted.
Read more →XTLBGeneral
▲ +98.3%on this news· ran to +134% by day 3shared move
XTL To Aquire The Social Proxy
XTL Biopharmaceuticals Ltd. has announced a binding term sheet to acquire The Social Proxy, a web data AI company. The acquisition will involve issuing shares representing 44.6% of XTL's outstanding capital and a payment of $430,000. The deal aims to enhance XTL's asset portfolio in the high-growth AI web data market. The transaction is contingent upon several conditions, including shareholder approval.
Read more →XTLBGeneral
▲ +128.8%on this news· ran to +170% by day 3shared move
XTL To Aquire The Social Proxy expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Secured $1.5 Million in a Pr
XTL Biopharmaceuticals Ltd. has announced its plan to acquire The Social Proxy Ltd., a web data AI company, as part of a strategy to expand its IP portfolio. The transaction will involve XTL issuing shares representing approximately 44.6% of its outstanding share capital in exchange for Social Proxy’s shares and a cash payment of $430,000. XTL has secured $1.5 million through a private placement to support this acquisition. Both companies’ CEOs expressed optimism about the potential growth and value of this new collaboration.
Read more →XTLBGeneral
XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel
XTL Biopharmaceuticals Ltd. has confirmed that its operations in Israel remain unaffected by recent events, including a terrorist attack and the declaration of war. The company continues its normal activities and is closely monitoring the situation to ensure business continuity. CEO Shlomo Shalev reassured partners and shareholders of the company's stable operations.
Read more →XTLBFDA Updates
XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
XTL Biopharmaceuticals has received a notification from Nasdaq regarding a deficiency in its minimum bid price, which must be $1.00 per share. The company has 180 days to regain compliance, or it may face delisting. XTL plans to monitor its stock price and explore options to meet Nasdaq's requirements.
Read more →XTLBConferences/Events
▲ +6%on this news
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON FEBRUARY 23, 2023 To the shareholders of XTL Biopharmaceuticals Ltd.: Notice is hereby given that an Annual General Meeting (the " Annual Meeting ") of the s
XTL Biopharmaceuticals Ltd. has announced its Annual General Meeting to be held on February 23, 2023, at its attorney's offices in Bnei Brak, Israel. The meeting will cover several important agenda items, including the re-appointment of auditors and the election of board members. Shareholders are encouraged to attend and vote in person or via proxy. The company will provide a detailed auditor's report for the previous year during this meeting.
Read more →XTLBGeneral
XTL BIOPHARMACEUTICALS LTD. CONDENSED INTERIM UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2022 INDEX Page Condensed Interim Unaudited Consolidated Financial Statements - in U.S. dollars: Unaudited Condense
XTL BIOPHARMACEUTICALS LTD.
CONDENSED INTERIM UNAUDITED CONSOLIDATED FINANCIAL
Page Condensed Interim Unaudited Consolidated Financial Statements - in U.S. dollars: Unaudited Condensed Consolidated Statements of Financial Position 2 Unaudited Condensed Consolidated Stateme
Read more →XTLBConferences/Events
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JANUARY 19, 2022 To the shareholders of XTL Biopharmaceuticals Ltd.: Notice is hereby given that an Annual General Meeting (the " Annual Meeting ") of the sh
ANNUAL GENERAL MEETING OF SHAREHOLDERS
TO BE HELD ON JANUARY 19, 2022
To the shareholders of XTL Biopharmaceuticals
Notice is hereby given that an Annual General
Meeting (the "Annual Meeting") of the shareholders of XTL Biopharmaceuticals Ltd. (the "Company") will
be held at
Read more →XTLBGeneral
▲ +12.8%on this news
OPERATING AND FINANCIAL REVIEW AND PROSPECTS You should read the following discussion and analysis in conjunction with the financial statements and the notes thereto included elsewhere in this 6-K. The tables below prese
OPERATING AND FINANCIAL REVIEW AND PROSPECTS
You should read the following
discussion and analysis in conjunction with the financial statements and the notes thereto included elsewhere in this 6-K.
The tables below present selected
financial data for the six months ended as o
Read more →XTLBGeneral
NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MARCH 29, 2021 To the shareholders of XTL Biopharmaceuticals Ltd.: Notice is hereby given that an Extraordinary General Meeting (the "Meeting") of the
EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
TO BE HELD ON MARCH 29, 2021
To the shareholders of XTL Biopharmaceuticals
Notice is hereby given that an Extraordinary
General Meeting (the "Meeting") of the shareholders of XTL Biopharmaceuticals Ltd. (the "Company") will
be he
Read more →XTLBConferences/Events
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 31, 2020 To the shareholders of XTL Biopharmaceuticals Ltd.: Notice is hereby given that an Annual General Meeting (the "Annual Meeting") of the sha
ANNUAL GENERAL MEETING OF SHAREHOLDERS
TO BE HELD ON DECEMBER 31, 2020
To the shareholders of XTL Biopharmaceuticals
Notice is hereby given that an Annual General
Meeting (the "Annual Meeting") of the shareholders of XTL Biopharmaceuticals Ltd. (the "Company") will
be held a
Read more →XTLBGeneral
NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 30, 2020 To the shareholders of XTL Biopharmaceuticals Ltd.: Notice is hereby given that an Extraordinary General Meeting (the "Meeting") of the
GENERAL MEETING OF SHAREHOLDERS
BE HELD ON JUNE 30, 2020
the shareholders of XTL Biopharmaceuticals Ltd.:
is hereby given that an Extraordinary General Meeting (the "Meeting") of the shareholders of XTL Biopharmaceuticals
Ltd. (the "Company") will be held at the offices of th
Read more →XTLBGeneral
GENERAL MEETING OF SHAREHOLDERS
GENERAL MEETING OF SHAREHOLDERS
BE HELD ON JANUARY 22, 2020
the shareholders of XTL Biopharmaceuticals Ltd.:
is hereby given that an Annual General Meeting (the "Meeting") of the shareholders of XTL Biopharmaceuticals Ltd.
(the "Company") will be held at the offices of the Co
Read more →XTLBGeneral
To the shareholders of XTL Biopharmaceuticals
MEETING OF SHAREHOLDERS
To the shareholders of XTL Biopharmaceuticals
Notice is hereby given that an Annual General
Meeting (the "Meeting") of the shareholders of XTL Biopharmaceuticals Ltd. (the "Company") will be held
at the offices of the Company's attorneys, Doron Tikotzk
Read more →XTLBGeneral
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 20, 2018 To the shareholders of XTL Biopharmaceuticals Ltd.: Notice is hereby given that an Annual General Meeting (the "Meeting") of the shareholde
GENERAL MEETING OF SHAREHOLDERS
BE HELD ON DECEMBER 20, 2018
the shareholders of XTL Biopharmaceuticals Ltd.:
is hereby given that an Annual General Meeting (the "Meeting") of the shareholders of XTL Biopharmaceuticals Ltd.
(the "Company") will be held at the offices of the C
Read more →XTLBGeneral
www.
www. xtlbio. com XTL Biopharmaceuticals ( NASDAQ: XTLB) ( TASE: XTLB. TA) November 2018
Forward Looking Statements Certain statements in this presentation are forward - looking within the meaning of the Private Securities Litigation Reform Act of 1995 . These statements may be i
Read more →XTLBGeneral
EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
To the shareholders of XTL Biopharmaceuticals
Notice is hereby given that an Extraordinary
General Meeting (the "Meeting") of the shareholders of XTL Biopharmaceuticals Ltd. (the "Company") will
be held at the offices of the Compa
Read more →XTLBGeneral
2017 ANNUAL GENERAL MEETING OF SHAREHOLDERS
2017 ANNUAL GENERAL MEETING OF SHAREHOLDERS
TO BE HELD ON JULY 27, 2017
To the shareholders of XTL Biopharmaceuticals
Notice is hereby given that an Annual General
Meeting (the "Meeting") of the shareholders of XTL Biopharmaceuticals Ltd. (the "Company") will be held
at the
Read more →XTLBGeneral
XTL BIOPHARMACEUTICALS ANNOUNCES $2.5 MILLION REGISTERED DIRECT OFFERING Raanana, Israel
XTL BIOPHARMACEUTICALS ANNOUNCES $2.5
MILLION REGISTERED DIRECT OFFERING
Raanana, Israel, February 17, 2017 -
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE:XTLB.TA) ("XTL" or the "Company"), a clinical-stage
biopharmaceutical company developing treatments for autoimmune di
Read more →XTLBGeneral
www.xtlbio.com XTL Biopharmaceuticals (NASDAQ: XTLB) (TASE: XTLB.TA) January 2017
www.xtlbio.com XTL Biopharmaceuticals (NASDAQ: XTLB) (TASE: XTLB.TA) January 2017
Forward Looking Statements Certain statements in this presentation are forward - looking within the meaning of the Private Securities Litigation Reform Act of 1995 . These statements may be identif
Read more →XTLBGeneral
OPERATING AND FINANCIAL REVIEW AND PROSPECTS You should read the following discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included els
OPERATING AND FINANCIAL REVIEW AND PROSPECTS
the following discussion of our operating and financial condition and prospects in conjunction with the financial statements
and the notes thereto included elsewhere in this 6-K, as well as in our Annual Report on Form 20-F filed on
Read more →XTLBGeneral
In accordance with Regulation 7 of the Israeli Companies Regulations
Proxy Card - Part One
In accordance with Regulation 7 of the Israeli Companies Regulations
(written voting and position statements), 2005 (the "Regulations").
Company Name XTL Biopharmaceuticals Ltd. (the "Company") Type of meeting An Annual General Meeting of Company Sharehol
Read more →XTLBGeneral
September 2015 www.xtlbio.com
September 2015 www.xtlbio.com
XTL Biopharmaceuticals (NASDAQ: XTLB) (TASE: XTL)
Looking Statements The following slides contain forward-looking statements, about XTL's expectations, beliefs or intentions
regarding, among other things, its product development efforts, business,
Read more →XTLBGeneral
XTL Biopharmaceuticals Appoints Dr. Jonathan Schapiro MD and Dr. Dobroslav Melamed to the Board of Directors to Help Lead Development of its Clinical Assets
XTL Biopharmaceuticals Appoints Dr. Jonathan
Schapiro MD and Dr. Dobroslav Melamed to
the Board of Directors to Help Lead Development of its Clinical Assets
HERZLIYA, Israel - December 08, 2014 - XTL
Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"),
Read more →XTLBGeneral
January 2014 www.xtlbio.com XTL Biopharmaceuticals (NASDAQ: XTLB) (TASE: XTL) Forward Looking Statements The following slides contain forward - looking statements that include, but are not limited to, projections about o
January 2014 www.xtlbio.com XTL Biopharmaceuticals (NASDAQ: XTLB) (TASE: XTL)
Forward Looking Statements The following slides contain forward - looking statements that include, but are not limited to, projections about our business and our future revenues, expenses, activities a
Read more →XTLBGeneral
of Extraordinary General Meetings and Further Changes to Board
of Extraordinary General Meetings and Further Changes to Board
Cottage, New York, August 27, 2008 -
Biopharmaceuticals Ltd. (NASDAQ: XTLB; TASE: XTL) today announced a notice
convening two Extraordinary General Meetings (the "Meetings"). The Meetings will
take place at the Co
Read more →XTLBGeneral
Unassociated Document Notification of Annual General Meeting and Extraordinary General Meeting Valley Cottage, New York
of Annual General Meeting and Extraordinary General Meeting
Cottage, New York, June 11, 2008 -
Biopharmaceuticals Ltd. (NASDAQ: XTLB; TASE: XTL) today announced a notice
convening its Annual General Meeting ("AGM") and Extraordinary General Meeting
("EGM"). The AGM and EGM wi
Read more →XTLBGeneral
XTL Provides Update on HepeX-B Program
NEW YORK, July 19, 2006 (PRIMEZONE) -- XTL Biopharmaceuticals, Ltd. (Nasdaq:XTLB) (LSE:XTL) (Tel Aviv:XTL) provided today an update on HepeX-B -- a drug candidate for the prevention of re-infection with Hepatitis B following liver transplantation.
HepeX-B was discovered and deve
Read more →XTLBGeneral
XTL Biopharmaceuticals Ltd. Provides Update to 2005 Annual Report on Form 20-F
NEW YORK, June 2, 2006 (PRIMEZONE) -- XTL Biopharmaceuticals Ltd., (Nasdaq:XTLB) (LSE:XTL) (TASE:XTL) ("XTL"), a biotechnology company focused on the acquisition, development and commercialization of therapeutics for the treatment of infectious diseases, with a focus on hepatitis
Read more →